Can buspirone be used as monotherapy for major depressive disorder?

Buspirone Should NOT Be Used as Monotherapy for Major Depressive Disorder

Buspirone is FDA-approved exclusively for anxiety disorders, not for depression, and should not be used as standalone treatment for major depressive disorder. 1

FDA Indication and Guideline Evidence

The FDA label for buspirone explicitly states it is "indicated for the management of anxiety disorder or the short-term relief of the symptoms of anxiety"—there is no FDA approval for depression monotherapy 1. The American College of Physicians guidelines on treating major depressive disorder 2, 3 consistently recommend second-generation antidepressants (SSRIs, SNRIs, bupropion, mirtazapine, nefazodone, trazodone) as first-line pharmacotherapy, with no mention of buspirone as a monotherapy option.

Role in Depression Treatment: Augmentation Only

Buspirone's legitimate role in depression treatment is as an augmentation agent, not monotherapy:

• When added to antidepressants like citalopram in treatment-resistant depression, buspirone shows efficacy comparable to bupropion augmentation, though bupropion is superior in reducing depression severity 3
• The 2016 ACP guideline discusses buspirone exclusively in the context of augmentation strategies for patients who failed initial antidepressant treatment 3
• Recent evidence (2025) confirms buspirone's effectiveness as adjunctive therapy for anxiety symptoms in depressed patients already taking SSRIs or SNRIs 4

Limited and Conflicting Monotherapy Data

While older research studies (1990-1998) explored buspirone monotherapy for depression 5, 6, 7, 8, the results were mixed and never translated into clinical guideline recommendations or FDA approval:

• One elderly population study showed 61% moderate-to-marked improvement with buspirone versus 42% with placebo, but this was inferior to imipramine (70%) 5
• Another study showed 70% improvement versus 35% placebo, but required doses up to 90 mg/day 6, 8
• These studies are over 25 years old and have been superseded by modern evidence-based guidelines

What You Should Do Instead

For initial treatment of major depressive disorder, select either:

1. Cognitive behavioral therapy (CBT), or
2. A second-generation antidepressant (SSRI, SNRI, bupropion, mirtazapine)

This recommendation is based on moderate-quality evidence showing equivalent efficacy between CBT and SGAs 3. When choosing an SGA, base selection on adverse effect profiles, cost, and patient preferences—not on superior efficacy, as no SGA demonstrates greater effectiveness than others 2.

If the patient fails initial treatment after 6-8 weeks 2, consider:

• Switching to a different SGA
• Augmenting with buspirone (though bupropion augmentation shows superior depression severity reduction) 3
• Augmenting with cognitive therapy

Critical Caveats

• Never use buspirone as monotherapy for depression—it lacks FDA approval and guideline support for this indication
• Buspirone carries risks of serotonin syndrome when combined with other serotonergic agents 1
• The drug is contraindicated with MAOIs due to risk of elevated blood pressure 1
• Monitor all antidepressant-treated patients closely for suicidality, especially in the first 1-2 weeks 2